In October, Sanofi initiated a patent infringement lawsuit against Mylan’s new drug application for a generic version of Lantus. Mylan responded by challenging Sanofi’s patents at the PTAB in an IPR.
Lantus is a prescription medicine for improving glycemic control in adult patients with diabetes.
Heather Bresch, CEO of Mylan, commented: “The PTAB's decision to institute IPR proceedings against the two Orange Book-listed patents for Lantus is another step forward in our ongoing efforts to bring an interchangeable insulin glargine to diabetes patients as soon as possible.”
She said: “There are more than 29 million people in the US living with diabetes who deserve access to more affordable treatment options. As a leading producer of oral diabetes medicines, we are deeply committed to this patient community and believe bringing lower-cost alternatives to Lantus and Lantus SoloSTAR will fulfill a critical medical need."